neuroendocrine tumor
Conditions
Interventions
FastPDTX pharmacodynamic test group:Individualized chemotherapy
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged from 18 to 70 years, male or female; (2) Patients with relapsed and refractory neuroendocrine tumors diagnosed by histopathological examinations require anticancer drug treatment; (3) Be able to obtain fresh tumor tissue by surgical resection or biopsy; (4) With objective tumors that meet the RECIST 1.1 standard, CT/MRI can be used to evaluate the efficacy; (5) ECOG score 0~2, expected survival period must be >= 3 months; (6) Subjects participated voluntarily, signed an informed consent form, had good compliance, and were able to actively treat and cooperate with follow-up. Books, good compliance, can actively treat and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: (1) At the same time participate in other drug clinical research; (2) Liver, kidney function and bone marrow hematopoietic function do not meet the requirements of chemotherapy; (3) Unwilling to use the anti-cancer drugs and/or programs recommended by the investigator in combination with the test results for subsequent chemotherapy after the failure of the previous treatment; (4) People suffering from severe uncontrolled acute infection or major organ diseases; (5) Women who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;DCR;Serum tumor markers; | — |
Countries
China
Contacts
Public ContactTang Qi-Yun
The First Affiliated Hospital with Nanjing Medical University
Outcome results
None listed